Top in endocrinology: Social stigma in diabetes; empagliflozin adjunctive therapy
Click Here to Manage Email Alerts
Most adults with type 1 or type 2 diabetes in the United States reported experiencing social stigma, and many also reported that this stigma impacted their decision to not use an insulin pump or continuous glucose monitoring device, data show.
“These findings really highlight that not only can we confirm there is a relationship between diabetes stigma and people’s willingness to use these devices, but it’s probably a more complex one than we were initially thinking,” Matthew Garza, BS, stigma program manager at the diaTribe Foundation in San Francisco, said during a presentation.
It was the top story in endocrinology last week.
The second top story covered data showing that, compared with placebo, empagliflozin as an adjunctive therapy to hybrid closed-loop insulin therapy was associated with improvements in time in range among patients with type 1 diabetes, according to a speaker at the International Conference on Advanced Technologies & Treatments for Diabetes.
Read these and more top stories in endocrinology below:
Most US adults with diabetes report social stigma
More than 60% of adults with type 2 diabetes and nearly 80% of those with type 1 diabetes said they experience some form of diabetes-related social stigma, according to survey data. Read more.
Empagliflozin as adjunctive therapy improves time in range in type 1 diabetes
Adults with type 1 diabetes spent more time in range with empagliflozin 2.5 mg or 5 mg as an adjunctive therapy to hybrid closed-loop insulin therapy compared with placebo, according to a speaker. Read more.
Eli Lilly announces $35 out-of-pocket insulin cap for people with commercial insurance
Adults with diabetes with commercial health insurance who use insulin manufactured by Eli Lilly and Company will have out-of-pocket costs capped at $35 per month, according to a company press release. Read more.
Most pituitary microadenomas do not change in size over 5 years of follow-up
Most adults with incident pituitary microadenomas have no change in size or a decrease in size during a median follow-up of nearly 5 years, according to findings published in Annals of Internal Medicine. Read more.
Insulin pump with adaptive therapy settings improved time in range in type 1 diabetes
Adults with type 1 diabetes who used an automated insulin delivery system with settings changed by the system instead of a provider had improvements in time in range and HbA1c at 13 weeks, according to a speaker. Read more.